Publicaciones en colaboración con investigadores/as de Pfizer (United States) (7)

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

2017

  1. Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

    Scientific Reports, Vol. 7

2015

  1. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

    British Journal of Cancer, Vol. 113, Núm. 1, pp. 12-19

2014

  1. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 2, pp. 76-82

2011

  1. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial

    The Lancet, Vol. 378, Núm. 9807, pp. 1931-1939

  2. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain

    Clinical and Translational Oncology, Vol. 13, Núm. 12, pp. 869-877

2009

  1. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

    Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812